The New York Times, December 6, 2013

Bowing to the Food and Drug Administration, the genetic testing service 23andMe said Thursday that it would stop providing consumers with health information while its test undergoes regulatory review. The decision was in response to a warning letter sent by the agency two weeks ago saying that the genetic test was a medical device that requires approval. "We remain firmly committed to fulfilling our long-term mission to help people everywhere have access to their own genetic data and have the ability to use that information to improve their lives," Anne Wojcicki, the chief executive of 23andMe, said in a statement Thursday evening.
Facebook icon
LinkedIn icon
Twitter icon